Page last updated: 2024-08-24

ranolazine and Pulmonary Hypertension

ranolazine has been researched along with Pulmonary Hypertension in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
de Lima Conceição, MR; Leal-Silva, P; Roman-Campos, D; Teixeira-Fonseca, JL1
Chan, SY; Forfia, P; Han, Y; Mazurek, JA; Park, MH; Ramani, G; Vaidya, A; Waxman, AB1
Alemanni, M; Altomare, C; Barile, L; Cornaghi, L; Gobbi, M; Latini, R; Lucchetti, J; Mostacciuolo, G; Rizzetto, R; Rocchetti, M; Ronchi, C; Russo, I; Sala, L; Staszewsky, LI; Zambelli, V; Zaza, A1
Belardinelli, L; Chi, L; Dhalla, AK; Hoyer, K; Liles, JT; Oliver, J1
Fragakis, N; Gong, M; Li, G; Liu, T; Zhang, C; Zhang, Z1
Farber, HW; Finch, KT; Stratton, EA1

Trials

1 trial(s) available for ranolazine and Pulmonary Hypertension

ArticleYear
Ranolazine Improves Right Ventricular Function in Patients With Precapillary Pulmonary Hypertension: Results From a Double-Blind, Randomized, Placebo-Controlled Trial.
    Journal of cardiac failure, 2021, Volume: 27, Issue:2

    Topics: Heart Failure; Humans; Hypertension, Pulmonary; Quality of Life; Ranolazine; Stroke Volume; Ventricular Dysfunction, Right; Ventricular Function, Right

2021

Other Studies

5 other study(ies) available for ranolazine and Pulmonary Hypertension

ArticleYear
Ranolazine exerts atrial antiarrhythmic effects in a rat model of monocrotaline-induced pulmonary hypertension.
    Basic & clinical pharmacology & toxicology, 2023, Volume: 132, Issue:5

    Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Heart Atria; Hypertension, Pulmonary; Monocrotaline; Ranolazine; Rats; Rats, Wistar

2023
Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
    Cardiovascular research, 2014, Oct-01, Volume: 104, Issue:1

    Topics: Acetanilides; Animals; Calcium Signaling; Collagen; Disease Models, Animal; Fibrosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Membrane Potentials; Monocrotaline; Myocytes, Cardiac; Myosin Heavy Chains; Piperazines; Pulmonary Artery; Ranolazine; Rats; Rats, Sprague-Dawley; Sodium; Sodium Channel Blockers; Sodium Channels; Time Factors; Vascular Remodeling; Vascular Resistance; Ventricular Function, Right; Ventricular Remodeling

2014
Ranolazine reduces remodeling of the right ventricle and provoked arrhythmias in rats with pulmonary hypertension.
    The Journal of pharmacology and experimental therapeutics, 2015, Volume: 353, Issue:3

    Topics: Acetanilides; Animals; Arrhythmias, Cardiac; Collagen; Electrocardiography; Enzyme Inhibitors; Fibrosis; Hypertension, Pulmonary; In Vitro Techniques; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley; Ventricular Remodeling

2015
Ranolazine as a novel therapy for pulmonary arterial hypertension.
    International journal of cardiology, 2016, Nov-15, Volume: 223

    Topics: Animals; Humans; Hypertension, Pulmonary; Ranolazine; Sodium Channel Blockers; Treatment Outcome; Vascular Resistance; Ventricular Dysfunction, Right

2016
Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: A pilot study.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2016, Volume: 35, Issue:11

    Topics: Aged; Cardiovascular Agents; Female; Heart Failure; Humans; Hypertension, Pulmonary; Male; Pilot Projects; Ranolazine; Stroke Volume

2016